A multicenter randomized phase 4 trial comparing sodium picosulphate plus magnesium citrate vs. polyethylene glycol plus ascorbic acid for bowel preparation before colonoscopy. The PRECOL trial

Autor: Valentina D’Angelo, Maria Carmela Piccirillo, Massimo Di Maio, Ciro Gallo, Cristina Bucci, Corrado Civiletti, Elena Di Girolamo, Pietro Marone, Giovanni Battista Rossi, Alfonso Mario Tempesta, Maura C. Tracey, Marco Romano, Agnese Miranda, Domenico Taranto, Gabriella Sessa, Pasquale Esposito, Raffaele Salerno, Rossella Pumpo, Francesca Romana De Filippo, Elisabetta Della Valle, Mario de Bellis, Francesco Perrone

Publikováno v: Frontiers in Medicine, Vol 9 (2022)

BackgroundAdequate bowel preparation before colonoscopy is crucial. Unfortunately, 25% of colonoscopies have inadequate bowel cleansing. From a patient perspective, bowel preparation is the main obstacle to colonoscopy. Several low-volume bowel prepa

Externí odkaz: https://doaj.org/article/5f6cf9bd23ad4f748a8d6dca85fe5ca9

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

Autor: Piera Gargiulo, Laura Arenare, Cesare Gridelli, Alessandro Morabito, Fortunato Ciardiello, Vittorio Gebbia, Paolo Maione, Alessia Spagnuolo, Giuliano Palumbo, Giovanna Esposito, Carminia Maria Della Corte, Floriana Morgillo, Gianfranco Mancuso, Raimondo Di Liello, Adriano Gravina, Clorinda Schettino, Massimo Di Maio, Ciro Gallo, Francesco Perrone, Maria Carmela Piccirillo

Publikováno v: BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)

Abstract Background Chemotherapy-induced neutropenia (CIN) has been demonstrated to be a prognostic factor in several cancer conditions. We previously found a significant prognostic value of CIN on overall survival (OS), in a pooled dataset of patien

Externí odkaz: https://doaj.org/article/a4ff3976bddf475882f1ba7ca7d1a374

Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system

Autor: Diana Giannarelli, Lucia Del Mastro, Fabio Efficace, Vincenzo Montesarchio, Roberto Bordonaro, Silvia Riva, Jane Bryce, Francesco De Lorenzo, Laura Del Campo, Massimo Di Maio, Luciano Frontini, Lara Gitto, Elisabetta Iannelli, Claudio Jommi, Francesca Traclò, Concetta Maria Vaccaro, Ciro Gallo, Francesco Perrone, Camillo Porta, Vittorina Zagonel, Laura Arenare, Saverio Cinieri, Maria Carmela Piccirillo, Anna Gimigliano, Lorenzo Guizzaro, Daniela Barberio, Alessio Aligi Cogoni

Publikováno v: BMJ Open, Vol 11, Iss 10 (2021)

Objectives To measure and explain financial toxicity (FT) of cancer in Italy, where a public healthcare system exists and patients with cancer are not expected (or only marginally) to pay out-of-pocket for healthcare.Setting Ten clinical oncological

Externí odkaz: https://doaj.org/article/e9f3af75e2734075b922f079ada930a9

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

Autor: Sandro Pignata, Giovanni Scambia, Clorinda Schettino, Laura Arenare, Carmela Pisano, Davide Lombardi, Ugo De Giorgi, Claudia Andreetta, Saverio Cinieri, Carmine De Angelis, Domenico Priolo, Claudia Casanova, Marta Rosati, Filippo Greco, Elena Zafarana, Ilaria Schiavetto, Serafina Mammoliti, Sabrina Chiara Cecere, Vanda Salutari, Simona Scalone, Alberto Farolfi, Marilena Di Napoli, Domenica Lorusso, Piera Gargiulo, Daniela Califano, Daniela Russo, Anna Spina, Rossella De Cecio, Paolo Chiodini, Francesco Perrone, Valentina Accinno, Chiara Altavilla, Giovanna Antonelli, Grazia Artioli, Francesco Avola, Bonifacio Barbara, Valentina Barbato, Michele Bartoletti, Simona Bevilacqua, Roberto Bordonaro, Oriana Borghese, Gaetano Buonfanti, Floriana Camarda, Giuliana Canzanella, Vittoria Carbone, Maria Rita Carbone, Giulia Carlo Stella, Chiara Cassani, Fabrizio Castagna, Monica Cattaneo, Margherita Cinefra, Nicoletta Colombo, Serena Corsetti, Monia Dall'Agata, Maria D'Amico, Gennaro Daniele, Elvira De Marino, Giovanni De Matteis, Sabino De Placido, Gabriella Del Bene, Antonia Del Giudice, Francesca Del Monte, Michele Del Sesto, Maddalena Donini, Giuliana Drudi, Gianluca Falcone, Adolfo Favaretto, Giulia Ferrera, Manuela Florio, Valeria Forestieri, Maria Stella Gallo, Ciro Gallo, Francesca Garibaldi, Fabiana Gerevini, Viola Ghizzoni, Maria Olga Giganti, Anna Gimigliano, Elena Giudice, Nicoletta Gnocchi, Adriano Gravina, Stefano Greggi, Maria Laura Iaia, Annalisa Ilardi, Gelsomina Iovine, Gabriella Ippoliti, Giulia Irollo, Ilenia Isidori, Mariateresa Lapresa, Giuseppe Lavenia, Laura Longhitano, Bortot Lucia, Gabriella Luzi, Sara Mariano, Valentina Marino, Giovanna Marrapese, Marilena Martino, Roberta Matocci, Enrica Mazzoni, Daniela Mercuri, Maria Mirto, Giovanna Mollo, Abbondanza Montinaro, Marta Moscatelli, Anna Maria Mosconi, Lucia Musacchio, Nicoletta Nanni, Pamela Natalucci, Milena Sabrina Nicoloso, Michele Orditura, Gabriella Maria Parma, Rodolfo Passalacqua, Michela Pelone, Maria Teresa Perri, Bruno Perrucci, Alessandra Piancastelli, Maria Carmela Piccirillo, Antonio Piccolo, Stefania Rapisardi, Giorgia Ravaglia, Teresa Ribecco, Caterina Ricci, Marianna Roccio, Fiorella Romano, Daniela Sambataro, Alfonso Savio, Ada Sbriglia, Cono Scaffa, Concetta Sergi, Francesca Sgandurra, Roberto Sorio, Stefano Stabile, Gianna Tabaro, Margherita Tambaro, Stefano Tamberi, Angelica Tecchiato, Angela Maria Trujillo, Eleonora Zaccarelli

Publikováno v: The Lancet Oncology. 24:286-296

Background: Adding immunotherapy to first-line chemotherapy might improve outcomes for patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin and paclitaxel versus avelumab plus carboplatin and paclitaxel as first-lin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2431afb32030e7d11f084ebe105f6204
https://doi.org/10.1016/s1470-2045(23)00016-5

A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan

Autor: Paolo Chiodini, Laura Arenare, Maria Carmela Piccirillo, Francesco Perrone, Ciro Gallo

Publikováno v: Contemporary Clinical Trials Communications, Vol 20, Iss , Pp 100665- (2020)

Background: Tocilizumab, an IL-6 receptor antagonist, was suggested as a possible treatment of severe or critical COVID-19 pneumonia in a small Chinese study. The TOCIVID-19 trial evaluates efficacy and tolerability of tocilizumab in the treatment of

Externí odkaz: https://doaj.org/article/264d1f4da11a4c50b4cd0613f29b4ddf